| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 10, 2004
Accepted on October 18, 2004
Unidad de Reproducción y Desarrollo, Facultad de Ciencias Biológicas, Departamento de Obstetricia y Ginecologia, Facultad de Medicina, Pontificia Universidad Católica de Chile, Alameda 340, Santiago, Chile; Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital, London W12 0NN, United Kingdom; Department of Medicine, Division of Endocrinology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
* To whom correspondence should be addressed.
Gareth I Owen, E-mail: gowen{at}bio.puc.cl
Progesterone in hormonal preparations increases the incidence of breast cancer. Tissue factor (TF), the initiator of the extrinsic coagulation pathway, is associated with metastasis in a wide variety of cancers. We demonstrate herein that TF mRNA and protein is up-regulated by progesterone in the breast cancer cell line ZR-75. EGF, also associated with increased breast cancer risk, did not regulate TF. The increase in TF is both rapid and transient; increasing after 6 h, reaching a maximum at 24 h, before decreasing to basal levels at 72 h. Sucrose gradient experiments demonstrated that TF is located in the heavy fraction of the plasma membrane, although caveolin-1 is not expressed in ZR-75. To understand the physiological implications of an increase in TF we performed coagulation and invasion assays. An increase in TF corresponded to an increase in procoagulant activity. Furthermore, progesterone increased the invasion of ZR-75 cells through a matrigel, an effect which was blocked by an antibody against TF. As TF expression is associated with an enhanced risk of metastasis, we postulate that the progesterone-dependent up-regulation of TF provides a survival advantage to burgeoning breast cancer cells and may contribute to the increased risk of cancer associated with combined HRT.
This article has been cited by other articles:
![]() |
E. Bicaku, D. C. Marchion, M. L. Schmitt, and P. N. Munster Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor-Mediated Signaling Cancer Res., March 1, 2008; 68(5): 1513 - 1519. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |